http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Selecta Biosciences Announces New Employment Inducement Grants
-
Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate Update
-
Selecta Biosciences to Present at the Stifel Healthcare Conference 2018
-
Selecta Biosciences to Report Third Quarter 2018 Financial Results and Update on SEL-212 Development Strategy, including Planned Head-to-Head Study versus Krystexxa
-
Selecta Biosciences (SELB) Presents New Interim Data from Phase 2 Trial of SEL-212
-
Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018
-
Selecta Biosciences to Present New Five Monthly Dose Phase 2 Data for SEL-212 in Chronic, Severe Gout at Upcoming 2018 ACR Annual Meeting
-
Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
-
Selecta Biosciences (SELB) Names Carsten Brunn Ph.D. as President and CEO
-
Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive Officer
-
Selecta Biosciences to Present at the Cantor Fitzgerald Global Healthcare Conference on October 02, 2018
-
Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018
-
Selecta Biosciences to Present at the Janney Healthcare Conference on September 17, 2018
-
Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)
-
Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update
-
Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2018
-
Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call
-
Selecta Biosciences (SELB) Highlights Data from Ongoing Phase 2 Trial of SEL-212 at EULAR 2018
-
Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
-
Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
-
Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 06, 2018
-
Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update
-
Selecta Biosciences Announces Date of First Quarter 2018 Financial Results Conference Call
-
Selecta Biosciences to Present at Upcoming Investor Conferences
-
Selecta Biosciences (SELB) Announces Positive New Data from Ongoing Phase 2 Trial of SEL-212 for Chronic Severe Gout Treatment
-
Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress
-
Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress on April 10, 2018
-
Selecta Biosciences to Present at the Needham Healthcare Conference on March 27, 2018
-
Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
-
Selecta Biosciences (SELB) Doses First Patient in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination
-
Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma
-
Selecta Biosciences to Report Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15, 2018
-
Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of R
-
Selecta Biosciences (SELB) Reports CEO's Intent to Retire and Transition Plan
-
Selecta Biosciences (SELB) Announces FDA Acceptance of IND for LMB-100 and SVP-Rapamycin Combination Therapy
-
Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy
-
Selecta Biosciences Announces CEO’s Intent to Retire and Transition Plan
-
Selecta Biosciences to Webcast Investor Conference Presentations This Week
-
Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
-
Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017
-
Selecta Biosciences Announces Important Additions to Senior Leadership Team
-
Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations
-
Selecta Biosciences to Participate in Upcoming Investor Conferences
-
Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update
-
Selecta Biosciences to Report Second Quarter 2017 Financial Results on Friday, August 11, 2017
-
Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2017
-
Selecta Biosciences (SELB) Reports $50M Private Placement of Common Stock
-
Selecta Biosciences Announces $50 Million Private Placement
-
Selecta Biosciences (SELB) Appoints Patrick Zenner to Board
-
Selecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors
